Overview

Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

Phase:

Phase 4

Details

Lead Sponsor:

Dova Pharmaceuticals